Polyclinique Bordeaux Nord Aquitaine

At Polyclinique Bordeaux Nord Aquitaine, the Service de Radiothérapie supports a broad portfolio of neoplasm studies focused on improving cancer care across solid tumors and blood cancers. Research here often evaluates new combinations, maintenance approaches, and personalized treatment strategies to improve survival, reduce recurrence, and refine post-treatment care.

• Studies in breast cancer, lung cancer, and colorectal cancer are testing more effective ways to control disease and prevent relapse.
• Lymphoma and multiple myeloma trials are exploring better treatment sequencing and disease control for hematologic cancers.
• Several projects assess whether adding targeted or immune-based therapies can improve outcomes after surgery or standard treatment.

The site’s work highlights a strong interest in radiotherapy combined with systemic treatment, with efforts aimed at making cancer therapy more precise, effective, and better tailored to each patient’s risk profile.

A major part of the research program centers on breast cancer, especially hormone receptor-positive, HER2-positive, HER2-low, and triple-negative breast cancer. These trials are designed to improve recurrence prevention, strengthen treatment responses in advanced disease, and support more personalized care after surgery or during metastatic treatment.

• Research includes strategies for early breast cancer, metastatic breast cancer, and isolated local or regional recurrence.
• Some studies examine targeted therapies for tumors with PIK3CA, BRCA, or ESR1 alterations.
• Other trials look at adding immunotherapy or endocrine-based approaches to improve disease control and delay progression.

This area reflects a strong focus on matching treatment to tumor biology, with the aim of improving long-term outcomes while reducing the chance of cancer returning.

The site also conducts extensive research in non-small cell lung cancer, including both resectable and advanced disease. These studies aim to improve outcomes after surgery, optimize neoadjuvant and adjuvant treatment, and evaluate newer targeted and immune-based therapies for patients with specific molecular features.

• Trials address resected NSCLC, locally advanced disease, and metastatic disease with molecular subtypes such as ROS1-positive cancer.
• Several studies test whether immunotherapy can reduce recurrence after surgery or improve disease control in advanced stages.
• Some projects examine personalized treatment decisions using tumor risk profiling and biomarker information.

The thoracic oncology portfolio shows a clear interest in combining radiotherapy, surgery, chemotherapy, and immunotherapy to improve survival and tailor care more precisely.

Research in digestive system diseases includes a wide range of cancers such as colon cancer, rectal cancer, gastric cancer, esophageal cancer, biliary tract carcinoma, pancreatic adenocarcinoma, and small bowel adenocarcinoma. The main goal is to improve cure rates, reduce relapse after surgery, and identify better systemic treatment options for advanced disease.

• Trials investigate adjuvant treatment decisions after surgery and strategies guided by ctDNA or tumor biology.
• Some studies focus on advanced or metastatic disease, testing combinations intended to improve tumor control and survival.
• Other projects explore whether treatment can be safely reduced in lower-risk patients without compromising outcomes.

This research area brings together gastrointestinal oncology and precision medicine, with a strong emphasis on matching treatment intensity to recurrence risk.

The site maintains active research in hemic and lymphatic diseases, particularly diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, peripheral T-cell lymphoma, and multiple myeloma. These studies aim to improve remission rates, prolong progression-free survival, and refine treatment choices for both newly diagnosed and relapsed disease.

• Trials examine whether newer combinations can outperform standard regimens in lymphoma.
• Myeloma research includes approaches for newly diagnosed patients, including those who are not candidates for intensive therapy.
• Some studies focus on minimal residual disease and response-adapted treatment planning.

This portfolio highlights a strong commitment to improving blood cancer care through more individualized and durable treatment strategies.

Beyond tumor-specific work, the research program includes studies in immune system diseases, diagnostic and analytical research, and supportive care. These trials often evaluate how biomarkers, imaging, or immune features can guide treatment selection, while others aim to manage symptoms and treatment-related effects more effectively.

• Several studies use ctDNA or other biomarkers to better detect recurrence risk and treatment response.
• Some trials explore ways to reduce symptoms such as vasomotor symptoms or treatment-related complications after cancer therapy.
• Research also includes supportive approaches for conditions like brain radionecrosis after radiotherapy.

This mix of diagnostic, immune-focused, and supportive care research reflects a broader effort to improve both the effectiveness and the tolerability of cancer treatment at the site.